Zurück zu Projekte

25253.1 PFLS-LS

25253.1 PFLS-LS

Zusammenfassung

Intermediate scale manufacturing and in vivo therapeutic assessment of a promising drug candidate for the treatment of GM1-gangliosidosis

Weitere Texte

Abstract

GM1-gangliosidosis is a rare orphan genetic disease caused by mutated forms of the lysosomal enzyme beta-galactosidase. DO-1 is a chaperone drug candidate that has been shown to rescue the defective enzyme activity in ex vivo patient cells. The current project proposes to perform critical steps in the preclinical development of DO-1, consisting in the set-up of its intermediate scale production route and the assessment of its therapeutic efficacy in a mouse model.

Beteiligte

Julie Charollais-Thoenig

Wirtschaftspartner

charollais@dorphan.com

Dorphan SA CHE-407.871.618 Julie Charollais-Thoenig Chemin de l'Eglise 7 1066 Epalinges VD CH

Roger Marti

Kontaktperson

roger.marti@hefr.ch

HEIA-FR Haute Ecole d'ingénierie et d'archi de Fribourg Roger Marti Boulevard de Pérolles 80 1700 Fribourg FR CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2016-10-31
Enddatum
2018-03-31
Bewilligte Gesamtkosten
CHF 309800.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T115 Medical technology 100.0%